Acute Respiratory Distress Syndrome (ARDS) and Acute Respiratory Failure (ARF) Following Hematopoietic Stem Cell Transplantation


About this study

The purpose of this study is to deepen our understanding of the ARDS mechanism following transplantation through an analysis of cytokines, metabolomics and proteomics before ARDS occurs, and during the early phase of ARDS development.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult (age 18 or greater) patients who consent for enrollment in the study.
  • Have undergone allogeneic HSCT within 100 days or autologous HSCT within 30 days.

Exclusin Criteria: 

  • Subject transferred from another institution having already been admitted there for > 24h. This proposal seeks to create a biorepository whose purpose will be to determine mechanism of ARF/ARDS development based on initial hospital course. If a substantial part of a patient’s hospital course preceeds enrollment (and is affected by care received at another institution), we may not get meaningful insights into the ARDS mechanism by enrolling them well into the disease processes that are involved in the pathogenesis of ARDS.
  • ARDS at the time of hospital admission. Since this study is looking at the mechanisms of ARDS development, we would seek to enroll patients before ARDS develops. 
  • Patient’s goals of care are such that ICU transfer (and specifically use of noninvasive or mechanical ventilation) would not be considered. As such, these patients would not be able to develop the outcome of interest (ARDS).
  • Admitted for:
    1. Admission only for chemotherapy administration.
    2. Control of symptoms related to diarrhea, vomiting, dehydration due to inability to swallow, dysphagia, pain or mucositis. 

Eligibility last updated 12/7/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hemang Yadav, M.B.B.S.

Open for enrollment

Contact information:

Hemang Yadav M.B.B.S.

(507) 284-2416

More information


Publications are currently not available

Mayo Clinic Footer